An Overview of CAS 1451-83-8 and Its Manufacturers

Introduction

The chemical compound identified by its CAS (Chemical Abstracts Service) number 1451-83-8 is commonly known as Ergotamine Tartrate. This compound is primarily used in the medical field for the treatment of migraines and cluster headaches. As a pharmaceutical product, its manufacturing involves precise compliance with safety standards and regulatory guidelines. In this article, we will delve into the specifics of CAS 1451-83-8, including its properties, uses, and the manufacturers involved in its production.

Understanding Ergotamine Tartrate

Ergotamine tartrate is derived from ergot fungus, specifically from the Claviceps purpurea species, which grows on grains such as rye. It has a complex chemical structure that allows it to interact with serotonin receptors in the brain, leading to vasoconstriction, which alleviates headache symptoms. In addition to its use for migraines, ergotamine is also utilized in managing certain complications of childbirth and as a part of treatment regimens for other types of headaches.

The primary benefit of ergotamine tartrate is its efficacy in providing relief from severe headaches. It works by narrowing blood vessels around the brain and reducing the inflammation associated with migraine attacks. This compound is typically administered in tablet form, though it can also be delivered via sublingual or injectable routes. The ability to offer quick relief makes it a staple medication for patients who suffer from chronic migraines.

However, like many pharmaceuticals, ergotamine tartrate does come with potential side effects, including nausea, vomiting, and risk of rebound headaches if overused. For this reason, it is crucial that its use is monitored by healthcare professionals, ensuring that patients receive personalized treatment that maximizes benefits while minimizing risks.

Manufacturers of Ergotamine Tartrate

The manufacturing of ergotamine tartrate is a specialized process that requires adherence to strict pharmaceutical standards. Various companies worldwide have established themselves as manufacturers of this compound, producing it for both domestic use and global distribution. Some notable manufacturers include

1. Teva Pharmaceuticals As one of the largest generic pharmaceutical companies in the world, Teva Pharmaceuticals produces a wide range of medications, including ergotamine tartrate. The company emphasizes high-quality standards and utilizes advanced manufacturing techniques to ensure the efficacy of its products.

2. Mylan (now part of Viatris) Mylan has a long history in the pharmaceutical industry and is known for its commitment to accessible healthcare. The company manufactures ergotamine tartrate as part of its extended portfolio of migraine therapies, reflecting its dedication to treating this debilitating condition.

3. Sandoz A division of Novartis, Sandoz specializes in generic pharmaceuticals and biosimilars. The company produces ergotamine tartrate while focusing on sustainable manufacturing practices and quality assurance, ensuring that its products meet regulatory standards.

4. Hikma Pharmaceuticals Hikma is a global company that manufactures a range of injectable and non-injectable medications. The company's investment in research and development has enabled it to produce high-quality ergotamine tartrate, contributing to the overall market supply.

5. Accord Healthcare Accord is a rapidly growing pharmaceutical company that offers an extensive range of generic products, including ergotamine tartrate. The company is committed to improving patient outcomes and providing cost-effective healthcare solutions.

Regulatory Considerations

Given the medical implications of ergotamine tartrate, its production and distribution are governed by various regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Manufacturers must comply with Good Manufacturing Practices (GMP) and submit to regular inspections to ensure that their processes meet necessary safety and quality benchmarks.

Conclusion

In summary, CAS 1451-83-8, or ergotamine tartrate, plays a significant role in the treatment of migraines and other headache-related conditions. Its manufacturers, including Teva, Mylan, Sandoz, Hikma, and Accord, are pivotal in ensuring that this medication is produced safely and effectively. As ongoing research continues to explore new applications and formulations, the importance of high-quality manufacturing practices remains central to the healthcare industry's commitment to patient safety and well-being.